Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Fig. 2

Total pathological complete response (tpCR) rate and breast pathological complete response (bpCR) rate. A Per independent central review; B per local pathology review. Patients with missing or unevaluable pCR status were considered non-responders. Error bars show 95% CIs for the pCR rate in each group, which were calculated using the Wilson method. Comparison between groups was done using the Cochran-Mantel-Haenszel test stratified by the randomization strata, and the 95% CI for the between-group difference was calculated using the Wald method

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us